References in periodicals archive ?
PD-1 and CTLA-4 are agents of immune tolerance, says Khaled Barakat, a physicist who works on drug design at the University of Alberta in Edmonton, Canada.
We were able to show very clearly that CTLA-4 signaling is associated with increased adhesion to ICAM-1 and is important for IS stabilization.
Formalin-fixed paraffin tumor tissue was analyzed for the genes CTLA-4, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, PLZF, Foxp3, RORyt, CD27, and CD70.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
In the mid-1990s he theorized that CTLA-4 might prevent the immune system from mounting an effective response against tumors.
The patent granted to EvoGenix covers the development and use of Evibodies derived from CTLA-4 and related proteins.
Robert Iannone, Head of Immuno-Oncology, Global Medicines Development at AstraZeneca, said: Advances in our biomarker development will enable us to effectively identify patients who could benefit most from durvalumab monotherapy as well as those for whom the combination with other immunotherapies such as our anti- CTLA-4 inhibitor (tremelimumab) would be more effective.
The OCEANS clinical development programme will evaluate MEDI4736 as monotherapy and in combination with a CTLA-4 (tremelimumab) in lung cancer, across the spectrum of the disease.
The concept of overcoming immune tolerance in cancer has been clinically validated with the recent approval of ipilimumab, an anti- CTLA-4 antibody.
Co-inhibitory receptors on T-cells, such as PD-1 and CTLA-4, are key mediators of this process, and antibody blockade of these pathways restore T cell responses in mouse models of tumors, and have demonstrated clinical efficacy in cancer patients.
The latest such attempt resulted in the development of a drug called ipilimumab, or Yervoy, which is an antibody against the so-called CTLA-4 receptor.
In healthy people, CTLA-4 is a godsend because it's a natural brake on immune attacks, says Steven O'Day, director of the Melanoma Program at the Angeles Clinic and Research Institute in Santa Monica, Calif.